Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2017
Event: Entry into a Material Definitive Agreement regarding a senior secured convertible debenture.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The specific financial obligation disclosed is:
- Debt Instrument: 5% original issue discount senior secured convertible debenture.
- Principal Amount: $4,400,000.
- Original Maturity Date: September 30, 2017.
- Revised Maturity Date: December 15, 2017.
- Interest Obligation: Interest is payable on the outstanding principal from September 30, 2017, through December 15, 2017.
Material Changes
The Company entered into a Letter Agreement with Delafield Investments Limited to revise terms of the existing debenture:
- Maturity Extension: The maturity date was extended by approximately 2.5 months from September 30, 2017, to December 15, 2017.
- Waiver of Default: The Purchaser waived the Company's compliance with Section 8 of the Debenture, which required payment of principal and interest on the original maturity date (September 30, 2017).
- Scope of Waiver: The waiver is limited to the specific payment due on September 30, 2017, and does not waive any other existing events of default.
Outlook, Risks, and Contingencies
Management Commentary: The filing confirms that all terms of the Debenture remain unchanged except for the maturity extension and the specific waiver noted above.
Risks: The filing explicitly states that the waiver does not cover other potential events of default that may exist as of the agreement date. The Company remains obligated to pay interest during the extension period and principal upon the new maturity date.
Investor Verification Checklist
- Verify the current status of any other potential events of default under the Debenture, as the waiver is limited in scope.
- Confirm the Company's liquidity position to ensure it can meet the interest payments due between September 30, 2017, and December 15, 2017.
- Review the full text of the Letter Agreement (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Assess the likelihood of the Company refinancing or repaying the $4,400,000 principal by the new December 15, 2017, deadline.